Pyrimidine derivatives used as PI-3-kinase inhibitors

US8217035B2 · kind B2 · utility

Assignee

• Novartis AG · CH

Inventors

• Matthew Burger · Belmont, US
• Zhi-Jie Ni · Emeryville, US
• Sabina Pecchi · Oakland, US
• Gordana Atallah · Fremont, US
• Sarah Bartulis · Emeryville, US
• Kelly Frazier · Emeryville, US
• Aaron Smith · Fremont, US
• Joelle Verhagen · Emeryville, US
• Yanchen Zhang · Kensington, US
• Allan S. Wagman · Belmont, US
• Simon Ng · Walnut Creek, US
• Keith B. Pfister · Emeryville, US
• Daniel Poon · Piedmont, US
• Alicia Louie · Emeryville, US
• Teresa E. Pick · Danville, US
• Paul A. Barsanti · Emeryville, US
• Edwin J. Iwanowicz · Cranbury, US
• Wendy J. Fantl · Emeryville, US
• Thomas Hendrickson · Emeryville, US
• Mark Knapp · Oakland, US
• Hanne Merritt · Emeryville, US
• Charles Voliva · Emeryville, US
• Marion Wiesmann · Emeryville, US
• Xiaohua Xin · Emeryville, US

Key dates

• Filing date: Jan 22, 2007
• Grant date: Jul 10, 2012
• Expiry date: Dec 5, 2027

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D417/12
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

Phosphatidylinositol (PI) 3-kinase inhibitor compounds (I), their pharmaceutically acceptable salts, and prodrugs thereof; compositions of the new compounds, either alone or in combination with at least one additional therapeutic agent, with a pharmaceutically acceptable carrier; and uses of the new compounds, either alone or in combination with at least one additional therapeutic agent, in the prophylaxis or treatment of proliferative diseases characterized by the abnormal activity of growth factors, protein serine/threonine kinases, and phospholipid kinases.